MD Anderson and RaySearch form alliance to advance radiation therapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MD Anderson Cancer Center and RaySearch Laboratories formed a strategic alliance with the aim of enhancing cancer radiation therapy through several initiatives, including more precisely targeting of tumors and improving upon, and making more available, an existing radiation therapy called adaptive radiation therapy, currently only used at highly specialized care centers.

Traditionally, additional margins are set around the target area to allow for tumor movement and variations in how patients are positioned during treatment.

However, these margins do not always compensate for unexpected changes in the tumor and surrounding normal tissue over the full course of radiation treatment. Adaptive radiation therapy uses frequent imaging to give an up-to-date assessment of physical changes and enable precisely tailored treatment for each patient.

The partnership, which builds upon a previously established relationship between RaySearch and MD Anderson centered on RayCare, RaySearch’s new oncology information system, combines MD Anderson’s clinical data and expertise with the latest technology and platforms available through RaySearch and will focus on the following areas:

  • Integration of advanced imaging into the treatment planning process to help define the tumor targets better.

  • Management of changes in the tumor that may occur during treatment, and monitoring and adjusting treatment to accommodate each patient’s individual circumstances at any point during therapy.

  • Building software components with the aim of creating a new standard of care in radiation therapy.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login